Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 16, 2010, Pages 7449-7454

  Liang, Xing Jie ^a   Meng, Huan ^b,f   Wang, Yingze ^a   He, Haiyong ^a   Meng, Jie ^a,b   Lu, Juan ^a   Wang, Paul C ^c   Zhao, Yuliang ^b   Gao, Xueyun ^b   Sun, Baoyun ^b   Chen, Chunying ^a   Xing, Genmei ^b   Shen, Dingwu ^d   Gottesman, Michael M ^d   Wu, Yan ^a   Yin, Jun Jie ^e   Jia, Lee ^d  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^c HOWARD UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Drug resistance; Nanoimaging; Nanomedicine; Nanopharmaceutical

Indexed keywords

CISPLATIN; FULLERENE DERIVATIVE; GADOLINIUM; MULTIHYDRATED METALLOFULLERENE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA ADDUCT; DRUG ACCUMULATION; DRUG EFFECT; ENDOCYTOSIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; ENDOCYTOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOMEDICINE; NANOTECHNOLOGY; TRANSFERRIN;

MUS MUSCULUS;

EID: 77952193093     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909707107     Document Type: Article

References (50)

1. Gottlieb JA, Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621-628.
2. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320. (Pubitemid 41130944)
3. Borst P, Rottenberg S, Jonkers J (2008) How do real tumors become resistant to cisplatin? Cell Cycle 7:1353-1359.
4. Siddik ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
5. Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288. (Pubitemid 13005502)
6. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4): 1-8, discussion 37-38.
7. Liang XJ, Shen DW, Gottesman MM (2004) A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem 98:1599-1606.
8. Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC (1990) The role of glutathione in drug resistance. Cancer Treat Rev 17(Suppl A):45-50.
9. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495-535. (Pubitemid 351738162)
10. Liang XJ, Shen DW, Garfield S, Gottesman MM (2003) Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 63:5909-5916. (Pubitemid 37187492)
11. Safaei R, et al. (2005) Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 11:756-767. (Pubitemid 40116905)
12. Safaei R, et al. (2005) Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4:1595-1604. (Pubitemid 41556443)
13. McNeill DR, Wilson DM, 3rd (2007) A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 5:61-70. (Pubitemid 46246767)
14. Basu S, et al. (2009) Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA 106:7957-7961.
15. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361.
16. Hamelers IH, et al. (2009) High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin Cancer Res 15:1259-1268.
17. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE (1985) C60: Buckminsterfullerene. Nature 318:162-163.
18. Tabata Y, Murakami Y, Ikada Y (1997) Photodynamic effect of polyethylene glycolmodified fullerene on tumor. Jpn J Cancer Res 88:1108-1116. (Pubitemid 28021483)
19. Yin JJ, et al. (2009) The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials 30:611-621.
20. Yin JJ, et al. (2008) Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol Pharmacol 74:1132-1140.
21. Wang JX, et al. (2006) Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol 71:872-881.
22. Chen CY, et al. (2005) Multihydroxylated [Gd@C82(OH)22]n nanoparticles: Antineoplastic activity of high efficiency and low toxicity. Nano Lett 5:2050-2057.
23. MacFarland DK, et al. (2008) Hydrochalarones: A novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J Med Chem 51:3681-3683.
24. Xing GM, et al. (2008) The strong MRI relaxivity of paramagnetic nanoparticles. J Phys Chem B 112:6288-6291.
25. Bolskar RD, et al. (2003) First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc 125:5471-5478.
26. Kato H, et al. (2003) Lanthanoid endohedral metallofullerenols for MRI contrast agents. J Am Chem Soc 125:4391-4397. (Pubitemid 36512335)
27. Laus S, et al. (2005) Destroying gadofullerene aggregates by salt addition in aqueous solution of Gd@C(60)(OH)(x) and Gd@C(60)[C(COOH(2))](10). J Am Chem Soc 127:9368-9369.
28. Tang J, et al. (2006) Periodical variation of electronic properties in polyhydroxylated metallofullerene materials. Adv Mater 18:1458-1462. (Pubitemid 43893462)
29. Jiang W, Kim BY, Rutka JT, Chan WC (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3:145-150.
30. Liang XJ, Chen C, Zhao Y, Jia L, Wang PC (2008) Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Metab 9:697-709.
31. Da Ros T, Prato M (1999) Medicinal chemistry with fullerenes and fullerene derivatives. Chem Commun (Camb) 8:663-669. (Pubitemid 29184681)
32. Liang XJ, Mukherjee S, Shen DW, Maxfield FR, Gottesman MM (2006) Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 66:2346-2353. (Pubitemid 43294949)
33. Kawai K, Kamatani N, Georges E, Ling V (1990) Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cisdiamminedichloroplatinum(II). J Biol Chem 265:13137-13142. (Pubitemid 20234265)
34. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM (1995) Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: Cross-resistance and protein changes. Br J Cancer 71:676-683.
35. Shen DW, Liang XJ, Gawinowicz MA, Gottesman MM (2004) Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol 66:789-793.
36. Chauhan SS, et al. (2003) Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 88:1327-1334. (Pubitemid 36606353)
37. Liang XJ, et al. (2005) Trafficking and localization of platinum complexes in cisplatinresistant cell lines monitored by fluorescence-labeled platinum. J Cell Physiol 202:635-641.
38. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM (2004) Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 91:270-276. (Pubitemid 39037071)
39. Ambrose KR, Lowrey JS (1982) Effect of cis- and trans- dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo. Cancer Res 42:1769-1773. (Pubitemid 12103372)
40. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176.
41. Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetatoammine- dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1:981-989.
42. Larson CA, Blair BG, Safaei R, Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330.
43. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43.
44. Murphy EA, et al. (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105:9343-9348.
45. Kratschmer W, Lamb LD, Fostiropoulos K, Huffman DR (1990) Solid C60: A new form of carbon. Nature 347:354-358.
46. Sun B, Feng L, Shi Z, Gu Z (2002) Improved extraction of metallofullerenes with DMF at high temperature. Carbon 40:1591-1595. (Pubitemid 34623852)
47. Xing G, et al. (2004) Influences of structural properties on stability of fullerenols. J Phys Chem B 108:11473-11479.
48. Mikawa M, et al. (2001) Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 12:510-514. (Pubitemid 32704179)
49. Box HC, et al. (2002) Detection and characterization of formamido lesions in DNA by liquid chromatography-mass spectrometry. Radiat Res 158:538-542.
50. Dawidzik JB, et al. (2003) DNA damage measured by liquid chromatography-mass spectrometry in mouse fibroblast cells exposed to oxidative stress. Biochim Biophys Acta 1621:211-217.